



TO THE NATIONAL SECURITIES MARKET COMMISSION

Madrid, 1 April 2026

OTHER RELEVANT INFORMATION

In compliance with the disclosure obligations set forth in Article 227 of Law 6/2023, of 17 March, on Securities Markets and Investment Services, and as a follow-up to the disclosure of inside information sent to the National Securities Market Commission (Comisión Nacional del Mercado de Valores) and disclosed to the market on 29 September 2025 (with official registration number 2907), Laboratorios Farmacéuticos ROVI, S.A. (hereinafter "**ROVI**" or the "**Company**") hereby announces that the Asset Purchase Agreement signed between its subsidiary ROIS Phoenix Inc. (hereinafter "**ROIS Phoenix**" or the "**Buyer**") and Bristol Myers Squibb ("**BMS**") for the acquisition of a pharmaceutical manufacturing plant located in Phoenix, Arizona (United States of America) (the "**Plant**") together with a series of related assets and liabilities has been executed (the "**Operation**").

The consummation of the aforementioned Asset Purchase Agreement has taken place upon the satisfaction of the customary closing conditions for transactions of this nature and in the absence of any material adverse change since its execution.

As previously announced, in connection with the Operation, the Buyer has entered into a toll manufacturing agreement with BMS (the "Toll Manufacturing Agreement"), which governs the terms and conditions under which ROIS Phoenix will continue to manufacture for BMS at the Plant with the personnel required to ensure its operability under said terms and conditions that were previously disclosed.

The Operation represents a strategic acquisition for ROVI and a key milestone towards achieving its vision of becoming one of the leading global manufacturers of high-value-added injectables (pre-filled syringes, cartridges and vials).

Mr. Juan López-Belmonte Encina
Chairman and Chief Executive Officer
Laboratorios Farmacéuticos ROVI, S.A.

ROVI forward-looking statements

This communication contains forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that might cause the actual results, performance or achievements of ROVI, or its industrial results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The information contained in this communication represents the expectations and beliefs of ROVI as of the date hereof. ROVI wishes to state that future events or developments may cause these expectations and beliefs to change. However, while ROVI may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be considered to represent the expectations or beliefs of ROVI at any date after the date of this communication.

About ROVI

ROVI is a pan-European pharmaceutical company specialised in and dedicated to the research, development, contract manufacturing and marketing of small molecules and biological specialities. The company, which is undergoing continuous international expansion, has subsidiaries in Portugal, Germany, the United Kingdom, Italy, France and Austria, and has a diversified portfolio of more than 40 products, including its flagship product, bemiparin, which is available in more than 60 countries worldwide. ROVI also commercialises its internally developed enoxaparin biosimilar in Europe which is now present in approximately 60 countries. ROVI continues to develop ISM® Platform technology, a cutting-edge line of research in the field of prolonged drug release with proven advantages. For more information, visit www.rovi.es

ROVI contacts

Media:

Beatriz García

+34 662 570 818

bgarciasuarez@rovi.es

Investors:

Marta Campos

mcampos@rovi.es

Beatriz de Zavala

bdezavala@rovi.es

Victoria López-Belmonte

vlopez-belmonte@rovi.es